A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs PTG 200 (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms PRISM
- Sponsors Janssen Biotech
- 06 Nov 2019 According to an Protagonist Therapeutics media release, results from this study are expected in 2021.
- 06 Nov 2019 According to an Protagonist Therapeutics media release, the first patient has been dosed in this study.
- 30 Oct 2019 Planned End Date changed from 11 May 2021 to 13 May 2021.